The UCL Institute of Immunity and Transplantation (IIT) is an international centre of excellence in immunology research. It is a hub for experimental medicine, transferring novel research concepts into new diagnostic tools and therapeutic interventions for the local and global patient population.
Multidisciplinary research and training programs serve to educate scientists and health professionals. Joint working accelerates the implementation of novel immunotherapies as routine treatment.
The IIT aims to develop vaccinations, gene therapy and cell therapy to enhance immunity in patients with cancer and chronic infection, and to induce tolerance in autoimmune diseases and in patients receiving conventional or bioengineered transplants.
The research activities of the IIT are grouped in three research clusters, with each cluster containing two related programs of research::
The IIT is part of the UCL Division of Infection and Immunity. It is an
important component of the research strategy of the Academic Health
Science Centre of UCL-Partners. The IIT is developed in partnership
between UCL, Royal Free London NHS Foundation Trust and the Royal
Free Charity and is delivered in two phases: i) Phase I is a £6 million
investment providing newly refurbished space and was opened in June
2013; ii) Phase II will provide a new state of the art research building
which is due to open in 2017. A grant award from the UK-Research
Partnership Investment Fund provides £33 million funding to support
the construction the new research building.
Page last modified on 26 mar 15 14:45